GLS and astrocytoma (excluding glioblastoma): For ICC, a phase 1b clinical trial (NCT03528642) was performed to study the side effects and optimal dose of the glutaminase inhibitor telaglenastat in combination with radiation therapy and temozolomide for treating patients with IDH-mutated astrocytoma [48].